Nuvectis Reports Positive NXP200 Phase 1b Study Data
Nuvectis said the study demonstrated durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas.
Nuvectis said the study demonstrated durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas.